In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.
Study Type
OBSERVATIONAL
Enrollment
233
At inclusion : Questionnaire collecting data concerning the interruption of IVT treatment
Data collection up to 1 year after resumption of follow-up: visual acuity, OCT : optical coherence tomography, IVT treatment, complications
Centre Pôle Vision du val d'Ouest
Écully, France
Fondation Adolphe de Rothschild
Paris, France
Hôpital Lariboisière
Paris, France
Centre ophtalmologique Maison Rouge
Strasbourg, France
Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic
Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up
Time frame: Baseline (Before confinement) and 6 months after resumption of follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.